SD HEALTHCARE

Arcturus Therapeutics Regains Full Rights to Drug Candidate

San Diego-based Arcturus Therapeutics on Feb. 12 reassumed full rights to its flagship drug candidate, after CureVac opted out of development plans.

Scripps to Build Larger Behavioral Health Unit

Through a joint venture Scripps Health has planned a 120-bed behavioral health facility in Chula Vista that will replace a smaller behavioral health unit at Scripps Mercy Hospital.

Qualcomm Sells Mobile Health Subsidiary

Qualcomm Life was sold to private equity firm Francisco Partners. It will be renamed Capsule Technologies.

Tease photo

Potential Acquisition of NuVasive Draws Analyst Skepticism

A recent report stated that Smith & Nephew Plc has held talks to buy San Diego spine surgery company NuVasive. But analysts largely said the deal doesn’t make sense for the British firm.

Gossamer Bio Goes Public with Upsized $276M Offering

Gossamer Bio — a closely watched San Diego biotech during the government shutdown — made its public debut Feb. 8 with an upsized $276 million offering.

Report: NuVasive in Talks to be Acquired in $3B Deal

Smith & Nephew Plc has held talks to buy San Diego-based NuVasive, a spine surgery company that analysts have called an acquisition target.

Contest Offers $1 Million Prize for Healthcare Innovation

The Alliance Healthcare Foundation is offering a $1 million prize for health innovations for vulnerable populations in San Diego and Imperial Counties.

SDBJ Insider: Halozyme’s Platform Keeps Delivering For Company

The partnership deals just keep rolling in for Halozyme Therapeutics’ drug delivery technology.

Gossamer Bio Goes Public with Upsized $276M Offering

Gossamer Bio — a closely watched San Diego biotech during the government shutdown — made its public debut Feb. 8 with an upsized $276 million offering.

As Deadline Looms, Biotechs Take Stock of Last Government Shutdown

The government shutdown ended Jan. 25, but lingering effects are evident in San Diego life sciences, from a halted merger to initial public offerings.

Tease photo

Equillium Receives Orphan Drug Designations

The U.S. Food and Drug Administration granted orphan drug designations to San Diego-based Equillium’s drug candidate for the prevention and treatment of a tissue disease.

Biotech Investors Often Bet on Familiar Faces

FINANCE: Investors See Pluses In Past Success, Experience

San Diego biotech’s growing roster of rising stars and veteran leaders helped propel the region to new fundraising heights in 2018, observers say.

Neurocrine Reports Fourth Quarter Results

San Diego biotech Neurocrine’s fourth quarter earnings largely beat analyst expectations.

From Little Known to IPO: INmune Bio Raises $8.16 Million in Trading Debut

In the first biotech initial public offering of the year, La Jolla-based INmune Bio took in $8.16 million during its trading debut. The Nasdaq listing also raised the profile of what’s been a quiet operation.